financetom
Business
financetom
/
Business
/
Sleep Number Q2 Net Loss Widens, Revenue Declines; Shares Fall Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sleep Number Q2 Net Loss Widens, Revenue Declines; Shares Fall Pre-Bell
Jul 30, 2025 6:38 AM

09:06 AM EDT, 07/30/2025 (MT Newswires) -- Sleep Number ( SNBR ) reported a Q2 net loss Wednesday of $1.09 per diluted share, widening from a $0.22 loss a year earlier.

Four analysts polled by FactSet expected a $0.11 loss.

Revenue for the quarter ended June 28 was $327.9 million, down from $408.4 million a year earlier.

Four analysts polled by FactSet expected $357.4 million.

The company said it expects full-year 2025 net sales of about $1.45 billion, representing about a 14% year-over-year decline. Four analysts polled by FactSet expect full-year revenue of $1.52 billion.

Sleep Number ( SNBR ) shares were down 24% in recent Wednesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
European spirits makers jump after China drops provisional brandy measures
European spirits makers jump after China drops provisional brandy measures
Sep 1, 2024
(Reuters) - Shares in French spirit makers Remy Cointreau and Pernod Ricard rallied early on Thursday after China's commerce ministry said it will not impose provisional anti-dumping measures on brandy imported from the European Union. Shares in Remy, which jumped over 12%, were up 7% by 0851 GMT, while Pernod, which climbed as much as 12%, was up 4%. Pernod...
Alnylam Pharmaceuticals Reports Substantial Results of Vutrisiran's Phase 3 Study as Heart Disease Therapy
Alnylam Pharmaceuticals Reports Substantial Results of Vutrisiran's Phase 3 Study as Heart Disease Therapy
Sep 1, 2024
07:30 AM EDT, 08/30/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Friday that detailed results of its phase 3 study of vutrisiran showed a non-significant 30% reduction in the relative risk of death up to three years in the study's monotherapy group. Vutrisiran is an investigational therapy for treating ATTR amyloidosis with cardiomyopathy, a heart disease. Shares of...
Berry Expects to Meet Production Goals for 2024
Berry Expects to Meet Production Goals for 2024
Sep 1, 2024
07:35 AM EDT, 08/30/2024 (MT Newswires) -- Berry (BRY) said Friday it expects to meet its previously issued guidance for 2024. The company previously forecast midpoint annual guidance of 25,200 barrels of oil equivalent per day. The company said it holds necessary permits to complete its drilling program planned for this year and to support activity into 2025. Berry said...
Talos Energy President, CEO Duncan Steps Down; Mills Named Interim President, CEO
Talos Energy President, CEO Duncan Steps Down; Mills Named Interim President, CEO
Sep 1, 2024
07:48 AM EDT, 08/30/2024 (MT Newswires) -- Talos Energy ( TALO ) said Friday that President and Chief Executive Tim Duncan has stepped down, effective on Thursday. The company said Joseph Mills has been named interim president and CEO until a successor is in place. Mills is currently a board member of the energy company. Talos also said it continues...
Copyright 2023-2026 - www.financetom.com All Rights Reserved